Macquarie Group Ltd. Has $2.17 Million Holdings in Evolent Health Inc (EVH)
Macquarie Group Ltd. raised its position in Evolent Health Inc (NYSE:EVH) by 50.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,642 shares of the technology company’s stock after purchasing an additional 40,917 shares during the period. Macquarie Group Ltd. owned 0.18% of Evolent Health worth $2,165,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its position in shares of Evolent Health by 6.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 63,180 shares of the technology company’s stock valued at $1,409,000 after buying an additional 3,591 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Evolent Health by 3.1% during the 1st quarter. Geode Capital Management LLC now owns 130,053 shares of the technology company’s stock valued at $2,900,000 after buying an additional 3,889 shares in the last quarter. ETF Managers Group LLC purchased a new stake in shares of Evolent Health during the 2nd quarter valued at $102,000. BNP Paribas Arbitrage SA raised its position in shares of Evolent Health by 815.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after buying an additional 4,232 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Evolent Health by 68.5% during the 2nd quarter. Bank of Montreal Can now owns 10,480 shares of the technology company’s stock valued at $266,000 after buying an additional 4,260 shares in the last quarter. 95.38% of the stock is owned by hedge funds and other institutional investors.
Several analysts have recently weighed in on the stock. Robert W. Baird set a $35.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research cut shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Cowen restated an “outperform” rating and set a $33.00 price objective (down previously from $35.00) on shares of Evolent Health in a research report on Wednesday, August 9th. Cantor Fitzgerald restated a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a research report on Sunday. Finally, J P Morgan Chase & Co restated a “buy” rating on shares of Evolent Health in a research report on Friday, August 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $28.00.
Shares of Evolent Health Inc (NYSE EVH) traded down $0.05 during trading hours on Wednesday, reaching $12.95. 3,406,100 shares of the company were exchanged, compared to its average volume of 1,246,389. Evolent Health Inc has a one year low of $10.30 and a one year high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.
Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. The company had revenue of $107.90 million for the quarter, compared to analysts’ expectations of $104.49 million. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm’s revenue was up 79.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.26) EPS. equities analysts forecast that Evolent Health Inc will post -0.57 earnings per share for the current fiscal year.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health Inc (NYSE:EVH).
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.